Drug Trial Radar · NCT07905352
A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Sep 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-Blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of Simenafil Hydrochloride Tablets in the treatment of participants with Alzheimer's Disease
Conditions
- Alzheimer Disease
Interventions
Simenafil Hydrochloride Tablets 2.5 mgDrug
Simenafil Hydrochloride Tablets 1 tablet (2.5mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (10mg/tablet)
Simenafil Hydrochloride Tablets 5 mgDrug
Simenafil Hydrochloride Tablets 1 tablet (5mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (10mg/tablet)
Simenafil Hydrochloride Tablets 10 mgDrug
Simenafil Hydrochloride Tablets 1 tablet (10mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (5mg/tablet)
Placebo TabletsDrug
Simenafil Hydrochloride Tablets placebo 1 tablet (5mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (10mg/tablet)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)Time frame: 52 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital ,Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.